市场调查报告书
商品编码
1530865
2030 年呼吸设备市场预测:按产品类型、疾病/障碍、最终用户和地区进行的全球分析Respiratory Devices Market Forecasts to 2030 - Global Analysis By Product Type, Disease/Disorder, End User and By Geography |
根据 Stratistics MRC 的数据,2024 年全球呼吸设备市场规模将达到 227 亿美元,预计到 2030 年将达到 409 亿美元,预测期内复合年增长率为 10.3%。呼吸器是医疗设备。这些设备为无法独立呼吸的患者提供机械通气,氧气疗法设备提供补充氧气。呼吸器在急性和慢性环境中都很重要,可以增强呼吸功能、确保充足的氧气供应并改善患者的治疗结果。
根据世界卫生组织统计,2019年约有2.62亿人患有气喘,50万人死于气喘。
慢性阻塞性肺病(COPD)盛行率上升
慢性阻塞性肺病是全球发病率和死亡率的主要原因,增加了对人工呼吸器、氧气浓缩机和雾化器等各种呼吸设备的需求。随着越来越多的人被诊断出患有慢性阻塞性肺病,对有效管理和治疗方案的需求也在增加。呼吸器对于缓解慢性阻塞性肺病患者的症状、改善肺功能和提高生活品质至关重要。此外,对慢性阻塞性肺病(COPD)的认识和早期诊断的提高进一步推动了这些设备的采用,从而推动市场成长。
副作用和併发症的风险
呼吸设备出现副作用和併发症的风险,例如感染疾病、气道刺激和设备相关伤害,源于使用不当、设备故障和缺乏适当的维护。这些风险可能会恶化患者的治疗效果并降低治疗效果。此外,监管监督和需要进行广泛的临床试验来解决这些风险可能会延迟新设备的推出,并进一步阻碍市场扩张。
扩大并改善医疗设施
随着医院和诊所升级基础设施,他们越来越多地投资于尖端呼吸设备,以改善患者护理。改善医疗设施也将改善呼吸系统疾病的诊断和治疗,从而推动对人工呼吸器、氧气疗法设备和监测系统等设备的需求。此外,新兴市场医疗保健服务的扩展使以前服务不足的人群能够使用呼吸设备,进一步推动市场成长,并使全球呼吸设备的数量更加可靠。
治疗费用高
呼吸设备的高治疗成本是由于与这些设备相关的先进技术、製造复杂性和持续维护所造成的。昂贵的零件和研发投资导致价格上涨。因此,这种经济障碍限制了潜在客户群并减缓了新技术向服务欠缺地区的渗透,从而抑制了市场成长。有限的价格分布也会影响整体市场扩张和公平获得医疗保健的机会。
COVID-19 的影响
COVID-19 的爆发对呼吸设备市场产生了重大影响,推动了对人工呼吸器、氧气疗法机和其他呼吸支援设备的前所未有的需求。 COVID-19 患者的激增使世界各地的医疗保健系统不堪重负,导致这些设备的短缺和产量增加。製造商迅速扩大生产规模以满足迫切需求。此外,随着疫情提高了人们对呼吸系统健康的认识、医疗系统为未来的呼吸系统疾病危机做好准备以及个人优先考虑呼吸系统健康,对呼吸设备的需求可能会在大流行后持续存在。
监控设备产业预计在预测期内规模最大
监控设备领域预计将出现良好成长。呼吸监测设备对于评估和管理呼吸健康至关重要。这包括脉搏血氧饱和度分析仪、二氧化碳测量仪和肺活量计。这些设备提供即时资料,允许及时干预和个性化治疗计划。随着技术的进步,便携式且易于使用的监测设备变得越来越可用,改善了患者护理和治疗结果。
预计气喘领域在预测期内复合年增长率最高
预计气喘细分市场在预测期内将出现最高的复合年增长率。气喘呼吸装置对于控制和缓解这种慢性呼吸道疾病的症状至关重要。这些设备可提高用药依从性,提供准确的剂量,增强症状管理,并在气喘发作期间实现及时介入。透过更好地控制气喘症状,这些设备可以帮助改善生活质量,减少气喘发作频率,并最大限度地减少对紧急护理的依赖。
由于呼吸道疾病盛行率上升、污染水平上升和人口老化加剧,预计亚太地区在预测期内将占据最大的市场占有率。在大量患者数量和不断扩大的医疗基础设施的推动下,中国和印度等国家是主要贡献者。技术进步和政府改善医疗保健机会的倡议正在进一步推动市场成长。 COVID-19 大流行也增加了该地区对呼吸设备的需求。随着人们对呼吸健康的认识不断增强,预计市场在未来几年将持续扩张。
北美呼吸设备市场是由慢性阻塞性肺病和气喘等呼吸系统疾病的高盛行率建立和推动的。先进的医疗基础设施、高昂的医疗费用以及最尖端科技的广泛采用正在推动市场的成长。人们对呼吸系统健康的认识不断提高,加上老年人口的不断增加,正在推动市场的扩张。美国由于广泛的研发活动、有利的报销政策以及主要医疗设备製造商的强大影响力而在市场上占据主导地位。
According to Stratistics MRC, the Global Respiratory Devices Market is accounted for $22.7 billion in 2024 and is expected to reach $40.9 billion by 2030, growing at a CAGR of 10.3% during the forecast period. Respiratory devices are medical instruments used to assist or support breathing in patients with respiratory conditions. These devices provide mechanical ventilation for patients who cannot breathe independently, and oxygen therapy equipment, which delivers supplemental oxygen. Respiratory devices are critical in both acute and chronic settings, enhancing respiratory function, ensuring adequate oxygenation, and improving patient outcomes.
According to the WHO, in 2019, about 262 million people were suffering and 0.5 million people died from asthma.
Rising prevalence of chronic obstructive pulmonary disease (COPD)
COPD, a leading cause of morbidity and mortality worldwide, increases the demand for various respiratory devices such as ventilators, oxygen concentrators, and nebulizers. As more individuals are diagnosed with COPD, the need for effective management and treatment options grows. Respiratory devices are essential in providing symptomatic relief, improving lung function, and enhancing the quality of life for COPD patients. Additionally, increased awareness and early diagnosis of COPD further drive the adoption of these devices, boosting market growth.
Risk of side effects and complications
The risk of side effects and complications in respiratory devices, such as infections, airway irritation, or device-related injuries, stems from improper use, device malfunctions, or lack of proper maintenance. These risks can lead to adverse patient outcomes and diminished effectiveness of treatment. Additionally, regulatory scrutiny and the need for extensive clinical trials to address these risks can slow down the introduction of new devices, further hampering market expansion.
Expansion and improvement of healthcare facilities
As hospitals and clinics upgrade their infrastructure, they are more likely to invest in state-of-the-art respiratory devices to enhance patient care. Improved healthcare facilities also lead to better diagnosis and treatment of respiratory conditions, driving demand for devices like ventilators, oxygen therapy equipment, and monitoring systems. Additionally, expanding healthcare services in emerging markets brings respiratory devices to previously underserved populations; further boosting market growth and ensuring better respiratory health management globally.
High treatment costs
High treatment costs for respiratory devices arise from the advanced technology, manufacturing complexities, and ongoing maintenance associated with these devices. Expensive components and research & development investments contribute to elevated prices. Consequently, this financial barrier hampers market growth by restricting the potential customer base and slowing down the penetration of new technologies into underserved areas. Limited affordability also impacts overall market expansion and equitable healthcare access.
Covid-19 Impact
The covid-19 pandemic significantly impacted the respiratory devices market, driving unprecedented demand for ventilators, oxygen therapy devices, and other respiratory support equipment. The surge in covid-19 cases overwhelmed healthcare systems globally, leading to shortages and increased production of these devices. Manufacturers rapidly scaled up production to meet the urgent need. Additionally, the pandemic raised awareness of respiratory health, potentially leading to sustained demand for respiratory devices even post-pandemic, as healthcare systems prepare for future respiratory crises and individuals prioritize respiratory wellness.
The monitoring devices segment is expected to be the largest during the forecast period
The monitoring devices segment is estimated to have a lucrative growth. Respiratory monitoring devices are crucial for assessing and managing respiratory health. They include pulse oximeters, capnographs, and spirometers. These devices provide real-time data, enabling timely interventions and personalized treatment plans. With advancements in technology, portable and user-friendly monitoring devices are becoming increasingly accessible, enhancing patient care and outcomes.
The asthma segment is expected to have the highest CAGR during the forecast period
The asthma segment is anticipated to witness the highest CAGR growth during the forecast period. Respiratory devices for asthma are essential in managing and alleviating symptoms of this chronic respiratory condition. These devices improve medication adherence, offer precise dosage, enhance symptom management, and enable timely intervention during asthma attacks. By facilitating better control of asthma symptoms, these devices contribute to improved quality of life, reduced frequency of exacerbations, and minimized reliance on emergency care.
Asia Pacific is projected to hold the largest market share during the forecast period due to increasing prevalence of respiratory diseases, rising pollution levels, and a growing aging population. Countries like China and India are significant contributors, driven by large patient populations and expanding healthcare infrastructure. Technological advancements and government initiatives to improve healthcare access further boost market growth. The COVID-19 pandemic has also heightened demand for respiratory support devices in the region. As awareness of respiratory health increases, the market is expected to see sustained expansion in the coming years.
North America respiratory devices market is well-established and driven by high prevalence of respiratory conditions such as COPD and asthma. Advanced healthcare infrastructure, significant healthcare spending, and widespread adoption of cutting-edge technologies contribute to market growth. Increasing awareness about respiratory health, coupled with a growing elderly population, bolsters market expansion. The U.S. dominates the market due to extensive research and development activities, favourable reimbursement policies, and strong presence of major medical device manufacturers.
Key players in the market
Some of the key players profiled in the Respiratory Devices Market include Inogen, Inc., ResMed Inc., Medtronic plc, Fisher & Paykel Healthcare Corporation Limited, Dragerwerk AG & Co. KGaA, GE Healthcare, Masimo Corporation, Koninklijke Philips N.V., Invacare Corporation, Air Liquide Medical Systems, Hamilton Medical AG, Vyaire Medical, Inc., Getinge AB, Nihon Kohden Corporation, Smiths Medical, DeVilbiss Healthcare LLC, Asahi Kasei Corporation and Teleflex Incorporated.
In August 2023, GE Healthcare launched new wireless patient monitoring device, the CARESCAPE(TM) Remote Monitoring (RM) system. This advanced device is designed to enhance patient care by providing continuous, real-time monitoring of patients' vital signs without the need for wired connections.
In April 2021, Smiths Medical launched the Acapella choice blue vibratory positive expiratory pressure (PEP) therapy system. Acapella is designed to aid in the removal of secretions for patients who have cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, lung disease with secretory problems, and patients with atelectasis.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.